Table 2.

Patient and tumor characteristics by use of neoadjuvant chemotherapy versus upfront surgery.

Variable	Neoadjuvant therapy (N = 125)		Upfront Surgery (N = 166)		p-value
	n	(%)	n	(%)
Node positivity (categorized)					0.89
Node-positivity detected by imaging and non-palpable (	62	(49.6%)	81	(48.8%)
Node-positivity palpable (cN1-3)	63	(50.4%)	85	(51.2%)
Clinical N stage at initial diagnosis					0.001
N1 by imaging	56	(44.8%)	78	(47.0%)
N1 by palpation	51	(40.8%)	83	(50.0%)
N2/3	18	(14.4%)	5	(3.0%)
Clinical T stage					0.36
cT0	1	(0.8%)	0	(0.0%)
cT1b	6	(4.8%)	5	(3.0%)
cT1c	25	(20.0%)	30	(18.1%)
cT2	74	(59.2%)	112	(67.5%)
cT3	16	(12.8%)	11	(6.6%)
cT4a	1	(0.8%)	0	(0.0%)
cT4b	2	(1.6%)	5	(3.0%)
cT4c	0	(0.0%)	1	(0.6%)
cTis (DCIS)	0	(0.0%)	1	(0.6%)
cTx	0	(0.0%)	1	(0.6%)
Postoperative N stage					<.001
pN0	0	(0.0%)	5	(3.0%)
pN1	0	(0.0%)	102	(61.4%)
pN2	0	(0.0%)	39	(23.5%)
pN3	0	(0.0%)	20	(12.0%)
ypN0	71	(56.8%)	0	(0.0%)
ypN0 (i+)	2	(1.6%)	0	(0.0%)
ypN1	42	(33.6%)	0	(0.0%)
ypN2	8	(6.4%)	0	(0.0%)
ypN3	2	(1.6%)	0	(0.0%)
Tumor type					0.07
Invasive ductal	96	(76.8%)	123	(74.1%)
Invasive lobular	6	(4.8%)	20	(12.0%)
Other	23	(18.4%)	23	(13.9%)
Tumor receptor subtype					<.001
HR+/HER2+	33	(26.4%)	8	(4.8%)
HR+/HER2-	44	(35.2%)	141	(84.9%)
HR-/HER2+	13	(10.4%)	2	(1.2%)
HR-/HER2-	30	(24.0%)	5	(3.0%)
Missing	5	(4.0%)	9	(5.4%)
Unknown	0	(0.0%)	1	(0.6%)
Tumor grade					<.001
G1	3	(2.4%)	8	(4.8%)
G2	51	(40.8%)	107	(64.5%)
G3	65	(52.0%)	50	(30.1%)
Unknown	6	(4.8%)	1	(0.6%)

Note: Five patients who received neoadjuvant therapy other than chemotherapy are not shown here.